AbbVie vs Humana: why the prices moved differently

• ▲

  Quarterly results beat as new drugs offset Humira's decline AbbVie's revenue rose 10.2% to $16.99 billion and adjusted earnings per share jumped 22.9% to $3.65, with Skyrizi and Rinvoq each up about 24%. Management raised full-year profit guidance, showing the company is growing again despite Humira's 35.9% sales drop. This reassures investors and supports the stock.

  The latest earnings show the core business is growing and guidance was raised, a direct positive for the stock.

• ▲

  Epcoritamab combination cuts lymphoma progression risk by 51% In a late-stage trial, AbbVie and partner Genmab's drug epcoritamab plus standard chemotherapy reduced the risk of disease worsening or death by 51% in newly diagnosed diffuse large B-cell lymphoma. This is the first such success for a bispecific antibody in frontline treatment, strengthening AbbVie's cancer pipeline and lifting hopes for a new growth driver.

  A major clinical win in a large cancer market adds a potential new revenue stream and boosts investor confidence.

• ▲

  FDA grants two breakthrough designations for Temab-A The FDA gave AbbVie's experimental antibody-drug conjugate Temab-A two Breakthrough Therapy Designations, for colorectal and non-small cell lung cancer. This speeds up development and signals the drug may offer a big advantage over existing treatments. It adds to AbbVie's growing oncology pipeline and supports long-term growth.

  Breakthrough designations can accelerate approval and highlight pipeline strength, a positive for future sales.

• ▲

  EU approves Boey, a fast-acting short-duration frown-line treatment European regulators approved Boey, the first rapid-onset, short-duration neurotoxin for frown lines, with effects starting in as little as eight hours and lasting two to three weeks. This expands AbbVie's aesthetics portfolio with a differentiated product and could capture new demand, supporting the stock.

  A new approved product in aesthetics adds revenue potential and competitive edge.

• ▲

  AbbVie selected for 340B rebate pilot, easing discount burden The Trump administration picked AbbVie as one of 10 drugmakers for a pilot that lets companies pay rebates after purchase instead of giving upfront discounts under the 340B program. This could improve cash flow and reduce compliance risk, a modest positive for the stock.

  The pilot may reduce upfront costs and regulatory friction for AbbVie.

Based on 7 stories →

• ▲

  FDA approves JUVMO for Parkinson's disease The FDA approved JUVMO (tavapadon), the first selective D1/D5 agonist for Parkinson's, with U.S. launch set for October 2026. This adds a differentiated neuroscience drug to AbbVie's portfolio, supporting future revenue growth and lifting investor confidence.

  A major new drug approval directly expands AbbVie's revenue base and pipeline strength.

• ▲

  Zumilokibart succeeds in Phase 2 atopic dermatitis trial AbbVie's zumilokibart met the main goal in a Phase 2 study for atopic dermatitis, and the mid-dose will move into final-stage testing. This strengthens the immunology pipeline and offers a potential new treatment for a common skin condition, supporting long-term growth.

  Positive mid-stage trial results advance a key pipeline candidate, signaling future revenue potential.

• ▲

  ABBV-295 shows promising weight loss and long half-life Phase 1 data for ABBV-295 showed up to 9.8% weight loss and an 11-12 day half-life, supporting less frequent dosing. This opens a new market for AbbVie in obesity care, a high-growth area, and could become a significant future sales driver.

  Early data support a potential best-in-class obesity drug, a major new growth opportunity.

• ▲

  RINVOQ shows sustained vitiligo repigmentation in Phase 3 Phase 3 data show RINVOQ produced continued skin repigmentation in vitiligo through 76 weeks with no new safety issues. This supports a potential new use for a key drug, expanding its label and adding a new revenue stream if approved.

  Late-stage data support a new indication for a major drug, enhancing its growth prospects.

Based on 9 stories →

• ▲

  Qulipta hits Phase 3 goal in menstrual migraine Qulipta met the main goal and all secondary goals in a late-stage trial for menstrual migraine, a condition with no approved treatment. If approved, it opens a new market of over nine million U.S. patients, adding a fresh sales driver and supporting the stock.

  New clinical win expands a fast-growing drug into an untapped market, a clear positive for future revenue.

• ▲

  Rinvoq wins EU approval for juvenile arthritis European regulators approved Rinvoq for polyarticular juvenile idiopathic arthritis, its 11th EU use. This widens the label of a key growth drug already on track for about $10.2 billion in 2026 sales, reinforcing confidence in AbbVie's immunology growth.

  New regulatory approval directly expands a major growth drug's market and supports the bull case.

• ▲

  AI drug-discovery deals and EPKINLY approval AbbVie signed multi-year AI collaborations with Iambic and joined the AISB Bind network to speed up drug discovery, and Health Canada approved EPKINLY for relapsed follicular lymphoma. These broaden the pipeline and add a new approved use, supporting long-term growth.

  New partnerships and a new approval show pipeline expansion and fresh revenue potential.

• ▼

  Oncology sales fall on Imbruvica and IRA pricing First-half oncology sales dropped 2.8% to $3.28 billion as Imbruvica fell 27.1% on competition and Medicare drug-price changes. Newer drugs like Venclexta and Elahere grew but did not fully offset the decline, weighing on overall growth.

  A real counterweight: a key segment is shrinking due to competition and pricing pressure.

Based on 8 stories →

• ▼

  Apogee acquisition dilutes near-term earnings AbbVie closed its $10.9 billion purchase of Apogee Therapeutics, adding an experimental immunology drug but cutting adjusted earnings by $0.14 per share in 2026 and $0.46 in 2027. Profit won't get a boost until 2032, so near-term investors see lower earnings and the stock faces pressure.

  This is the main new negative event this period and directly lowers reported earnings, a key driver of the stock price.

• ▲

  Etentamig succeeds in Phase 3 myeloma trial AbbVie's experimental blood-cancer drug etentamig met both main goals in a late-stage trial, with a 74% response rate versus 46% for standard care and a 60% lower risk of disease worsening. This strengthens the oncology pipeline and raises hopes for a new growth driver, supporting the stock.

  This is a major new clinical win that expands AbbVie's cancer franchise and improves long-term growth prospects.

• ▲

  Qulipta succeeds in menstrual migraine trial AbbVie's migraine drug Qulipta hit the main goal in a Phase 3 trial for menstrual migraine, reducing migraine days with a convenient dosing schedule. Qulipta sales already grew 31% to $350 million last quarter, so a new use could add revenue and lift the stock.

  This is a new positive trial result that could expand the label and sales of an already fast-growing drug.

• ▲

  Neuroscience outlook raised on broad growth AbbVie lifted its 2026 neuroscience revenue forecast to about $12.7 billion and total revenue to roughly $67.6 billion, after first-half neuroscience sales jumped 21.8%. Strong demand across Vraylar, Botox, Qulipta, Ubrelvy and Vyalev gives investors more confidence in future profits, pushing the stock up.

  This is a new guidance raise that directly improves revenue expectations and signals broad-based demand strength.

Based on 8 stories →

• ▲

  Citadel boosts AbbVie stake by 547% Ken Griffin's Citadel bought 2.68 million more ABBV shares, a 547% increase, at an average of $214.90. A major fund raising its bet signals confidence in AbbVie's long-term value and can draw other investors in, supporting the stock price.

  Large institutional buying is a fresh, concrete signal of confidence that can lift investor sentiment and demand for the shares.

• ▲

  New lung cancer data strengthens oncology pipeline AbbVie presented promising early data for several experimental lung cancer drugs at a major conference, with high response rates and manageable side effects. This broadens its pipeline beyond immunology and neuroscience, giving investors another potential growth engine and supporting the stock.

  Fresh clinical progress on multiple oncology programs adds a new growth pillar, which can improve the long-term earnings outlook.

• ▲

  Skyrizi submitted for easier Crohn's dosing in Europe AbbVie asked European regulators to approve Skyrizi as a subcutaneous (under-the-skin) induction treatment for Crohn's disease, based on positive trial data. If approved, it offers patients a more convenient option and extends Skyrizi's reach, supporting future sales and the stock.

  A regulatory filing that could widen a key drug's use is a concrete pipeline expansion, not just a repeat of past results.

• ▼

  J&J's oral psoriasis pill approved in China Johnson & Johnson won Chinese approval for Icotyde, a once-daily pill for plaque psoriasis, a market with over 8.4 million patients where AbbVie's Skyrizi competes. A convenient oral option could take share from injectables like Skyrizi, weighing on AbbVie's growth prospects in China.

  This is a new competitive threat in a large market that could pressure sales of a key AbbVie drug.

Based on 7 stories →

• ▼

  Trump demands drug price cuts President Trump sent letters to major drugmakers, including AbbVie, demanding U.S. prescription price cuts within 60 days. This threatens future pricing power and revenue, pushing the stock down as investors worry about lower profits.

  This is a new regulatory threat that directly pressures AbbVie's pricing and future earnings.

• ▲

  Skyrizi and Rinvoq fuel growth AbbVie's newer immunology drugs Skyrizi and Rinvoq now make up over 47% of total revenue, with combined sales expected to exceed $31 billion this year. Their rapid growth is replacing declining Humira sales and supports the stock's long-term value.

  This shows the core business is successfully transitioning beyond Humira, a key driver of future revenue.

• ▲

  Neuroscience outlook raised AbbVie raised its 2026 neuroscience revenue forecast to about $12.7 billion, driven by strong sales of Vraylar, migraine drugs Ubrelvy and Qulipta, and Botox Therapeutic. This diversification adds a growing revenue stream and boosts investor confidence.

  This is a new positive update showing another part of AbbVie's business is performing well and raising guidance.

• ▼

  Epcoritamab trial fails survival goal Genmab and AbbVie confirmed that the Phase 3 trial of epcoritamab for a type of lymphoma did not meet its main overall survival goal. This pipeline setback could delay or reduce the drug's potential, weighing on sentiment.

  This is a new negative pipeline event that could hurt future oncology revenue prospects.

Based on 9 stories →

• ▲

  Q2 beat and raised revenue guidance AbbVie beat Q2 estimates with $3.65 EPS and $16.99B revenue, and raised full-year revenue guidance by $300M on strong Skyrizi, Rinvoq and neuroscience growth. This shows the core business is performing well, supporting the stock's long-term value.

  This is the main new positive event this period, directly driving the stock's fundamental outlook.

• ▼

  Full-year profit guidance lowered Despite the revenue beat, AbbVie cut its full-year adjusted earnings outlook, partly due to a $291M charge for acquired IPR&D and milestone expenses. This disappointed investors and caused shares to fall 4%, as it signals near-term profit pressure.

  This is the key negative event this period, explaining the immediate stock drop and investor concern.

• ▲

  EU approval of RINVOQ for alopecia areata AbbVie won European approval for RINVOQ in severe alopecia areata, expanding its immunology franchise. This adds a new revenue stream and reinforces RINVOQ's growth potential, which is positive for the stock.

  This is a new regulatory win that expands the market for a key drug, supporting future sales.

• ▼

  Epcoritamab trial setback The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint in the U.S., a setback for AbbVie's oncology pipeline. This could delay or reduce the drug's potential, weighing on sentiment.

  This is a new negative pipeline event that affects future growth prospects.

Based on 8 stories →

• ▲

  EU approval of TEPKINLY for follicular lymphoma The European Commission approved AbbVie's TEPKINLY combination for relapsed follicular lymphoma, a chemotherapy-free option that cut progression risk by 79%. This expands AbbVie's oncology portfolio and adds a new revenue stream, supporting long-term growth.

  New approval directly boosts AbbVie's oncology franchise and future sales.

• ▲

  EU approval of Boey for frown lines Allergan Aesthetics, part of AbbVie, won EU approval for Boey, a fast-acting botulinum toxin for frown lines. This strengthens AbbVie's aesthetics business and offers a new treatment option, potentially driving revenue growth.

  New product approval expands AbbVie's aesthetics portfolio and revenue potential.

• ▲

  Voluntary drug-pricing deals with Trump administration AbbVie agreed to voluntary most-favored-nation pricing with the Trump administration. While this may lower prices for some drugs, AbbVie's newer immunology drugs Skyrizi and Rinvoq are expected to offset Humira's decline, and the deal reduces regulatory uncertainty.

  New pricing agreement affects AbbVie's revenue but is manageable given strong new drugs.

• ▼

  Epcoritamab trial misses overall survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial did not meet its primary overall survival endpoint in the U.S. This setback could delay or reduce the drug's potential in this indication, weighing on sentiment.

  New negative trial result directly impacts AbbVie's oncology pipeline and investor confidence.

Based on 8 stories →

• ▲

  Apogee acquisition and expanded drug labels drive record high AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, adding a promising immunology drug. It also won approvals to expand Skyrizi and Rinvoq to new patient groups. These moves strengthen future growth and pushed the stock to a 52-week high, adding $43 billion in market value in a week.

  This is the main reason the stock hit a new high and reflects the biggest new development this period.

• ▼

  US Congress opens bipartisan probe into AbbVie's China clinical trials A House committee is investigating AbbVie's clinical trials in China, including sites linked to the Chinese military and in Xinjiang. While no illegal conduct is alleged, the probe could lead to tighter oversight, higher compliance costs, and restrictions on trial locations, potentially delaying drug pipelines and hurting the stock.

  This is a new risk that could negatively affect the stock and was not in earlier reports.

• ▼

  Growth of key drugs Skyrizi and Rinvoq shows signs of slowing Skyrizi's growth decelerated to 29.2% from 31.9%, and Rinvoq's growth slowed to 20.2% from 28.6%. These drugs are critical to AbbVie's post-Humira strategy, and any sustained slowdown could pressure the stock's valuation, which already prices in high growth.

  This is a new concern about the company's growth engine that could weigh on the stock.

• ▲

  Positive late-stage trial results and new drug approvals bolster pipeline AbbVie reported positive Phase 3 data for venetoclax in leukemia and epcoritamab in lymphoma, and won approvals for MAVIRET in hepatitis C, SKYRIZI in pediatric psoriasis, and a new neurotoxin Boey. These advances strengthen the company's oncology and aesthetics portfolios, supporting long-term revenue growth.

  These are new clinical and regulatory wins that reinforce AbbVie's pipeline and future sales potential.

Based on 23 stories →

• ▲

  Apogee acquisition adds promising immunology drug AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining zumilokibart, a potential rival to Dupixent for eczema and asthma. The deal strengthens AbbVie's immunology franchise and pipeline, which investors view as a positive for long-term growth.

  This is the main new event driving ABBV's stock and future prospects.

• ▲

  Deal funded without debt, preserving financial flexibility AbbVie will pay for Apogee entirely from operating cash flow, avoiding new debt. This keeps its balance sheet strong and reduces financial risk, which supports the stock price.

  Shows the acquisition is financially manageable and not a strain.

• ◆

  Near-term earnings dilution, but long-term growth The deal won't add to adjusted earnings per share until 2032, so it may slightly weigh on near-term profits. However, it positions AbbVie for future growth in immunology, balancing the short-term cost with long-term benefit.

  Highlights the trade-off investors are weighing.

• ▲

  Analysts see reasonable premium and strategic fit Citi and other analysts said the 49% premium is not excessive given Apogee's strong data and scarce immunology assets. The deal also fits with AbbVie's existing commercial infrastructure, supporting a positive view.

  Analyst validation reinforces the market's positive reaction.

Based on 6 stories →

• ▲

  Star Ratings Recovery Restores Bonus Payments CMS upgraded Humana's largest Medicare Advantage contract to 4 stars for 2027, and 95% of members will be in 4-star-plus plans, up from 20%. This restores federal quality bonus payments, boosting future earnings and lifting the stock 15%.

  This is the main new event that directly answers why HUM is moving, with a clear positive impact.

• ▲

  Analyst Upgrade on Improved Earnings Outlook Baird upgraded Humana to Outperform with a $596 price target, up from $390, citing confidence in $35-plus of 2028 adjusted EPS. This analyst endorsement reinforces the positive sentiment from the Star Ratings news.

  It shows a direct analyst reaction to the improved fundamentals, supporting the stock's move.

• ▲

  Expanded Coverage for Incontinence Device Humana will cover BlueWind Medical's Revi System for urgency urinary incontinence, expanding treatment access for its 11 million Medicare Advantage enrollees. This is a minor positive but shows Humana's role in adopting new technologies.

  It is a new coverage decision that could marginally improve Humana's reputation and member satisfaction.

• ▼

  Medicare Advantage Industry Retrenchment Centene is exiting 344 counties and three states for 2027, and Humana plans to exit 57 counties and Minnesota, as premiums are expected to decline 16.5%. This industry-wide pullback reflects ongoing pressure on Medicare Advantage profitability.

  It provides context on the challenging Medicare Advantage environment, a counterweight to the positive Star Ratings news.

Based on 8 stories →

• ▼

  Humana drops 600,000 Medicare Advantage members for 2027 Humana is cutting about 600,000 members from its Medicare Advantage plans next year, its second straight year of big cuts, to protect profit margins as medical costs rise. Fewer members means less premium revenue, which pressures the stock, though it may help margins.

  This is the core new event driving Humana's outlook and was confirmed in this period.

• ▲

  Star Ratings recovery targeted as key catalyst Humana aims to return to top-quartile Star Ratings by 2028, which would boost bonus payments and plan economics. Early progress is encouraging, and the October CMS ratings release is the next test. A rebound could support the stock, though shares already trade at a high valuation.

  Star Ratings recovery is a major potential upside driver for Humana's turnaround and margins.

• ▼

  Medicare fraud settlement and upcoding scrutiny The Villages Health settled a $541.5 million Medicare fraud case over inflated diagnosis codes. Humana's CenterWell unit is shielded from direct payment, but Humana received inflated payments and is returning overpayments. The case signals heightened government scrutiny on risk-adjustment practices, a regulatory risk for Humana.

  This highlights a regulatory overhang that could affect Humana's payments and reputation.

• ▼

  Sector-wide cost pressures and macro headwinds Managed care stocks, including Humana, fell after CVS Health warned of elevated medical costs. Rising oil prices and Treasury yields added to market pressure. These sector-wide concerns weigh on Humana's stock, though they are not specific to the company.

  This explains a broad negative sentiment affecting Humana's price during the period.

Based on 6 stories →

• ▼

  Medicare star rating drop cuts 2026 profit outlook Humana lowered its full-year GAAP earnings target to at least $6.52 per share from $8.36 because fewer plans earned four stars or more, reducing federal quality bonuses. This directly cuts expected profit and is the main reason the stock fell about 9% premarket.

  This is the biggest new negative event and explains the profit outlook cut.

• ▲

  Q2 earnings beat on membership and revenue growth Humana reported adjusted earnings of $7.61 per share, beating estimates by over 20%, with revenue up 26% to $40.9 billion and medical membership up 20.7% to 17.9 million. Strong results show the core business is growing, which supports the stock.

  This is a new positive counterweight to the profit outlook cut.

• ▼

  End of Medicare Part D subsidy raises 2027 premiums The Trump administration ended a subsidy that gave insurers about $3.6 billion in 2026. Without it, most enrollees will pay more in 2027, and insurers like Humana may see lower government payments and pressure on Part D margins, which is a negative for future profits.

  This is a new regulatory change that affects Humana's future Medicare Part D business.

• ▲

  Operational streamlining and growth initiatives Humana is targeting a 3% margin by 2028, exiting weaker Medicare Advantage plans, and expanding Medicaid and home health through a $900 million divestiture and the MaxHealth acquisition. These moves aim to improve long-term profitability and offset star rating issues.

  This shows management's plan to fix margins and grow, which is new and relevant to the big picture.

Based on 7 stories →

• ▲

  Illinois Medicaid win expands members Humana won a statewide Illinois Medicaid contract, adding members across all 102 counties starting January 2027. More members mean more premium revenue, which supports future earnings and makes the stock more attractive.

  New contract directly expands Humana's revenue base.

• ▼

  AI gains may be competed away UBS says hospitals may benefit more from AI than insurers because insurers' efficiency gains are easily copied and competed away through pricing. This limits how much Humana can improve margins from AI, a headwind for profit growth.

  Analyst view questions durability of insurer AI margin gains.

• ▼

  Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care among major Medicare Advantage insurers, including Humana. This raises regulatory and reputational risk, which could lead to stricter rules or fines, pressuring the stock.

  Regulatory scrutiny can hurt Humana's Medicare Advantage business.

• ▲

  Margin recovery plan and strong Q1 Humana beat Q1 earnings estimates and targets insurance margins above 3% by 2028, with disciplined pricing and cost cuts. Strong results and a clear profit plan boost investor confidence, pushing the stock up.

  New earnings and margin targets show improving profitability.

• ▲

  CenterWell drives growth beyond insurance CenterWell revenue jumped 19.7% to $6.1 billion, with growth in primary care, home health, and pharmacy. This diversification reduces reliance on insurance and adds a steady profit stream, supporting the stock.

  CenterWell's strong growth is a key new driver of Humana's value.

Based on 6 stories →